API drug development and manufacturing services

Scientific expertise that speeds your journey

The successful development and manufacture of small molecule active pharmaceutical ingredients (API) rests on speed, efficiency, and quality across your journey. We offer scientific expertise, world-class technology, and a comprehensive range of solutions to help you reach your clinical milestones quickly and accelerate your path to commercialization.

Partner with us to seamlessly align the development and manufacture of your small molecule API and finished drug product. We use an integrated one-team approach to deliver the power of our full network. The Patheon™ Quick to Clinic™ small molecule program is designed to accelerate your early development program for small molecules. We can also streamline your total drug substance and drug product development, demand planning, clinical trial, and commercial supply into a single customized solution with our Patheon™ Quick to Care™ program.

From early process optimization and scale-up to commercial production, we provide key services across the lifecycle to get your project to market. Our focus is always on your molecule—whether you require early-phase material or late-phase and commercial supply, we have the capabilities, expertise, and experience to meet your API needs.

API development and manufacturing services at Linz site

100+ commercial products
Supplying API to companies around the world

230+ small molecule projects
More than 230 active small molecule API projects in 2020, from preclinical through Phase II

89% RFT rate
Average right-first-time (RFT) rate of 89% in 2020

50 years of experience
Leading the industry in the manufacture of cGMP API since 1974

100+ commercial products
Supplying API to companies around the world

230+ small molecule projects
More than 230 active small molecule API projects in 2020, from preclinical through Phase II

89% RFT rate
Average right-first-time (RFT) rate of 89% in 2020

50 years of experience
Leading the industry in the manufacture of cGMP API since 1974

API CDMO solutions and capabilities


Route scouting 

Establishing the best synthetic route for your molecule is the basis for a reliable supply throughout your product’s lifecycle. During route scouting, we consider the following when selecting the ideal pathway: 

  • Safety
  • Efficiency, purity, and cost
  • Ease of optimization and scale-up
  • Intellectual property (IP) review
  • Security of supply of raw materials
  • Impact on waste and the environment 
Solid-state chemistry

Finding the most appropriate physical form for your API is critical, as this impacts the downstream performance of your product. Optimizing characteristics such as size and shape, particle size distribution, flow, density, bioavailability, and melting point enables more efficient formulation and manufacturing process development at the drug product stage. Our extensive capabilities and experience in solid-state chemistry ensure that you receive the best solid form for your drug product development and scale-up.

Helpful resources 

When you partner with us, you’ll work directly with scientists who have a deep knowledge of chemistry and many years of experience successfully supporting early- and late-phase clinical development programs and commercial-scale manufacturing. Our experts offer you cutting-edge capabilities in multistep chemical synthesis, for both traditional and complex API manufacturing.


Our experts offer a full range of capabilities and analytical services to execute with the highest degree of flexibility and deliver on time with exceptional yields and superior quality: 

  • Risk assessment and proven acceptable range (PAR) studies
  • Validation of analytical methods and manufacturing
  • Quality assurance and regulatory compliance support for the chemistry, manufacturing, and controls (CMC) portion of your submission, as needed
  • Technology transfers to move projects between facilities while preserving product supply and process efficiency

At our clinical development and commercial supply API manufacturing facilities, located in North America and Europe, teams of experts work continuously to optimize processes, increase outputs, and reduce timelines. All our facilities comply with cGMP and safety regulations and are routinely inspected by national regulatory agencies.

Technology transfers

We view technology transfers as an opportunity to use our integrated approach and our commitment to efficiency to give you a strategic and financial advantage. Tech transfers, for scale-up or to move a project between facilities, are part of our normal course of business. If the transfer is urgent, we can execute it quickly and effectively to get your project back on track and preserve your product supply. In all cases, we are driven by your deadlines, flexible in our approach, and determined to get it right the first time, every time.

Helpful resources 


Manufacturing process scale-up for Phase III: Clear sailing or storms ahead? 

Review the findings

Our team builds on a foundation of efficiency, effectiveness, and safety, using innovations in science and technology to continually improve your synthetic processes for marketed products. We also ensure that your process remains both competitive and cost-effective throughout the product lifecycle.

  • Our global expertise in technology transfers can help you quickly and reliably scale up production or shift production between sites
  • Advances in technology and the availability of safer reagents potentially result in fewer steps, faster processing time, greater yields, less environmental impact, and reduced cost 

Helpful resources 

We have analytical method development and quality control laboratories staffed by highly experienced teams within each of our manufacturing and development sites. Our experts will support your analytical needs at every phase of the clinical development and commercial-scale manufacturing process through highly reliable stability, purity, assay method development, and quality control testing procedures.

API analytical method development and lab services at Linz site
Particle size reduction

Uniform particle characteristics are fundamental when manufacturing a formulation-enabling API. Carefully defined particle size distribution can help improve flow properties, which are essential in drug product development and can improve solubility to increase your product’s bioavailability.


With experienced teams and leading technologies, we offer particle size reduction solutions for all stages of API development and commercial manufacture:

  • Milling capabilities from laboratory- to production-scale
  • Simple deagglomeration through coarse grinding
  • Micronization via numerous methods

Helpful resources 

Approximately 70-90% of new drugs in development have solubility and bioavailability challenges that require special attention when it comes to optimizing their formulation approach. Spray dried amorphous dispersions support the development of advanced drug formulations, helping to meet precise requirements that ensure bioavailability, stability, and manufacturability.

Although the process is well understood, spray drying requires high levels of technical capability and operational excellence. One of its key benefits is the production of amorphous particles with a controlled particle size distribution. The result is increased surface area, which enhances the contact between the solid particles and the solvent, leading to improved solubility overall.

Additionally, spray drying allows for the formation of amorphous powders, which exhibit enhanced solubility compared to its crystalline form.

Advantages of Thermo Fisher Scientific’s spray drying capabilities:
  1. Proven track records of success: We’ve progressed over 60 molecules to the next development phase. Every year, we complete ~50 tech transfers across 11 different sites based in North America and Europe
  2. Expertise in formulation and process development combined with proven capabilities in spray drying to overcome difficult product development challenges; 50+ years of API development and manufacturing experience
  3. Global capabilities from pre-clinical to commercial scale up: Teams from all sites are positioned to support technology transfer activities and collaborate with clients to mitigate risk through NDA and launch


Spray drying equipment at Florence site

Helpful resources